Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $55
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $68 to $55.
Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $68 to $55.